Task Force’s PSA Proposal Prompts Calls For More Research On Prostate Cancer Diagnostics
This article was originally published in The Gray Sheet
Executive SummaryOverdiagnosis and overtreatment of prostate cancers that result from screening with prostate-specific antigen tests highlight the need for research on new diagnostics technologies, suggests a new draft statement from the U.S. Preventive Services Task Force.
You may also be interested in...
While the PSA test is still widely recognized as a valuable prostate cancer screening tool, its dismal accuracy record has created an acute need for more effective and informative alternatives, and the field of molecular diagnostics, based on gene-based biomarkers, is leading the charge.
The final recommendations are a major shift in policy for the commonly performed blood test, and one certain to face ongoing controversy.
Data and trial updates in cardiology, oncology and more.